Literature DB >> 28799562

Ophthalmic features of spinocerebellar ataxia type 7.

A Campos-Romo1, E O Graue-Hernandez2, L Pedro-Aguilar2, J C Hernandez-Camarena2, D Rivera-De la Parra2,3, V Galvez1,4, R Diaz5, A Jimenez-Corona2, J Fernandez-Ruiz4,5.   

Abstract

PurposeTo analyze the relation between ophthalmologic and motor changes in spinocerebellar ataxia type 7 (SCA7).Patients and methodsThis was a case series study. Sixteen SCA7 patients underwent a comprehensive ophthalmic examination, including ocular extrinsic motility testing, color vision test, and optical coherence tomography of the optic nerve and macula. Changes in the corneal endothelium, electroretinographic patterns, and a complete neurologic evaluation using the Scale for the Assessment and Rating of Ataxia (SARA) were evaluated. Correlations of endothelial cell density (ECD) with number of CAG repetitions and the SARA scores were estimated.ResultsAll patients showed various degrees of visual impairment mainly due to macular deterioration. Notably, they also presented decreased ECD. Pairwise correlations of ECD with number of CAG repeats and severity of motor symptoms quantified with the SARA scores were inverse (r=-0.46, P=0.083 and r=-0.64, P=0.009, respectively). Further analyses indicated an average ECD decrease of 48 cells/mm2 (P=0.006) per unit of change on the number of CAG repeats, and of 75 cells/mm2 (P=0.001) per unit of change on the SARA scores.ConclusionsThe results agree with previous ophthalmological findings regarding the widespread effect of SCA7 mutation on the patient's visual system. However, the results also show a significant negative correlation of decreased ECD with both CAG repetitions and SARA scores. This suggests that motor systems could degenerate in parallel with visual systems, although more research is needed to determine whether the degeneration is caused by the same mechanisms.

Entities:  

Mesh:

Year:  2017        PMID: 28799562      PMCID: PMC5770701          DOI: 10.1038/eye.2017.135

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  30 in total

1.  Age-, tissue- and length-dependent bidirectional somatic CAG•CTG repeat instability in an allelic series of R6/2 Huntington disease mice.

Authors:  Eloise Larson; Ian Fyfe; A Jennifer Morton; Darren G Monckton
Journal:  Neurobiol Dis       Date:  2015-02-03       Impact factor: 5.996

2.  Evidence for a common founder effect amongst South African and Zambian individuals with Spinocerebellar ataxia type 7.

Authors:  Danielle C Smith; Masharip Atadzhanov; Mwila Mwaba; Leslie Jacqueline Greenberg
Journal:  J Neurol Sci       Date:  2015-05-09       Impact factor: 3.181

3.  Spinocerebellar ataxia type 7 (SCA7) - correlations between phenotype and genotype in one large Belgian family.

Authors:  J Martin; N Van Regemorter; J Del-Favero; A Löfgren; C Van Broeckhoven
Journal:  J Neurol Sci       Date:  1999-09-15       Impact factor: 3.181

4.  Comprehensive study of early features in spinocerebellar ataxia 2: delineating the prodromal stage of the disease.

Authors:  Luis Velázquez-Pérez; Roberto Rodríguez-Labrada; Edilia M Cruz-Rivas; Juan Fernández-Ruiz; Israel Vaca-Palomares; Jandy Lilia-Campins; Bulmaro Cisneros; Arnoy Peña-Acosta; Yaimeé Vázquez-Mojena; Rosalinda Diaz; Jonathan J Magaña-Aguirre; Tania Cruz-Mariño; Annelié Estupiñán-Rodríguez; José M Laffita-Mesa; Rigoberto González-Piña; Nalia Canales-Ochoa; Yanetza González-Zaldivar
Journal:  Cerebellum       Date:  2014-10       Impact factor: 3.847

5.  Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice.

Authors:  G Yvert; K S Lindenberg; S Picaud; G B Landwehrmeyer; J A Sahel; J L Mandel
Journal:  Hum Mol Genet       Date:  2000-10-12       Impact factor: 6.150

6.  Retinal degeneration characterizes a spinocerebellar ataxia mapping to chromosome 3p.

Authors:  L G Gouw; C D Kaplan; J H Haines; K B Digre; S L Rutledge; A Matilla; M Leppert; H Y Zoghbi; L J Ptácek
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

Review 7.  Polyglutamine neurodegeneration: protein misfolding revisited.

Authors:  Aislinn J Williams; Henry L Paulson
Journal:  Trends Neurosci       Date:  2008-09-06       Impact factor: 13.837

8.  Ophthalmic features of spinocerebellar ataxia type 7.

Authors:  Roslyn K Manrique; Susana Noval; María J Aguilar-Amat; Javier Arpa; Irene Rosa; Inés Contreras
Journal:  J Neuroophthalmol       Date:  2009-09       Impact factor: 3.042

9.  Spinocerebellar ataxias: genotype-phenotype correlations in 104 Brazilian families.

Authors:  Hélio A G Teive; Renato P Munhoz; Walter O Arruda; Iscia Lopes-Cendes; Salmo Raskin; Lineu C Werneck; Tetsuo Ashizawa
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 10.  The role of the immune system in triplet repeat expansion diseases.

Authors:  Marta Olejniczak; Martyna O Urbanek; Wlodzimierz J Krzyzosiak
Journal:  Mediators Inflamm       Date:  2015-03-22       Impact factor: 4.711

View more
  4 in total

Review 1.  Molecular Targets and Therapeutic Strategies in Spinocerebellar Ataxia Type 7.

Authors:  Anna Niewiadomska-Cimicka; Yvon Trottier
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

Review 2.  An Eye on Movement Disorders.

Authors:  Duncan Wilson; Mark Hallett; Tim Anderson
Journal:  Mov Disord Clin Pract       Date:  2021-08-10

Review 3.  Spinocerebellar ataxia clinical trials: opportunities and challenges.

Authors:  Sarah M Brooker; Chandrakanth Reddy Edamakanti; Sara M Akasha; Sheng-Han Kuo; Puneet Opal
Journal:  Ann Clin Transl Neurol       Date:  2021-05-21       Impact factor: 4.511

4.  Fuchs' Endothelial Corneal Dystrophy in Patients With Myotonic Dystrophy, Type 1.

Authors:  Nelson S Winkler; Margherita Milone; Jennifer M Martinez-Thompson; Harish Raja; Ross A Aleff; Sanjay V Patel; Michael P Fautsch; Eric D Wieben; Keith H Baratz
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-06-01       Impact factor: 4.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.